• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰腺神经内分泌肿瘤的治疗选择

Treatment Options for Pancreatic Neuroendocrine Tumors.

作者信息

Akirov Amit, Larouche Vincent, Alshehri Sameerah, Asa Sylvia L, Ezzat Shereen

机构信息

Institute of Endocrinology, Beilinson Hospital, Petach Tikva 49100, Israel.

Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.

出版信息

Cancers (Basel). 2019 Jun 14;11(6):828. doi: 10.3390/cancers11060828.

DOI:10.3390/cancers11060828
PMID:31207914
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6628351/
Abstract

The management of pancreatic neuroendocrine tumors (PanNETs) involves classification into non-functional or functional PanNET, and as localized or metastatic PanNET. In addition, while most PanNETs are sporadic, these endocrine neoplasms can also be manifestations of genetic syndromes. All these factors may assist in forming a risk stratification system permitting a tailored management approach. Most PanNETs are classified as non-functional because they are not associated with clinical sequelae of hormone excess. They are characterized by non-specific symptoms, such as abdominal pain or weight loss, resulting from mass effect related to the pancreatic tumor or secondary to distant metastases. Accurate staging of the disease is essential for determining the appropriate approach to therapy. As cure is only potentially possible with surgical resection of the tumor, it is recommended to remove all localized and limited metastatic disease. However, many patients present with metastatic and/or advanced local disease. In such instances, the goal of therapy is to control tumor growth and/or decrease tumor burden, lengthen survival, and palliate local symptoms and those of hormone excess. This typically requires a multimodal approach, including surgery, liver-directed treatment, and systemic medical therapy.

摘要

胰腺神经内分泌肿瘤(PanNETs)的管理包括将其分类为无功能或有功能的PanNET,以及局限性或转移性PanNET。此外,虽然大多数PanNETs是散发性的,但这些内分泌肿瘤也可能是遗传综合征的表现。所有这些因素可能有助于形成一个风险分层系统,从而允许采用量身定制的管理方法。大多数PanNETs被归类为无功能,因为它们与激素过多的临床后遗症无关。它们的特征是出现非特异性症状,如腹痛或体重减轻,这些症状是由胰腺肿瘤的占位效应或远处转移继发引起的。准确的疾病分期对于确定合适的治疗方法至关重要。由于只有通过手术切除肿瘤才有可能治愈,因此建议切除所有局限性和有限的转移性疾病。然而,许多患者表现为转移性和/或局部晚期疾病。在这种情况下,治疗的目标是控制肿瘤生长和/或减轻肿瘤负担,延长生存期,并缓解局部症状和激素过多的症状。这通常需要多模式方法,包括手术、肝脏定向治疗和全身药物治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5ae/6628351/994ca9158598/cancers-11-00828-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5ae/6628351/994ca9158598/cancers-11-00828-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5ae/6628351/994ca9158598/cancers-11-00828-g001.jpg

相似文献

1
Treatment Options for Pancreatic Neuroendocrine Tumors.胰腺神经内分泌肿瘤的治疗选择
Cancers (Basel). 2019 Jun 14;11(6):828. doi: 10.3390/cancers11060828.
2
Neuroendocrine pancreatic tumors: guidelines for management and update.神经内分泌胰腺肿瘤:管理和更新指南。
Curr Treat Options Oncol. 2012 Mar;13(1):24-34. doi: 10.1007/s11864-011-0172-2.
3
Surgery for metastatic pancreatic neuroendocrine tumors: a narrative review.转移性胰腺神经内分泌肿瘤的手术治疗:一项叙述性综述。
Hepatobiliary Surg Nutr. 2023 Feb 28;12(1):69-83. doi: 10.21037/hbsn-22-238. Epub 2023 Jan 16.
4
The Eighth Edition of the American Joint Committee on Cancer Distant Metastases Stage Classification for Metastatic Pancreatic Neuroendocrine Tumors Might Be Feasible for Metastatic Pancreatic Ductal Adenocarcinomas.美国癌症联合委员会第八版转移性胰腺神经内分泌肿瘤远处转移分期分类可能适用于转移性胰腺导管腺癌。
Neuroendocrinology. 2020;110(5):364-376. doi: 10.1159/000502382. Epub 2019 Jul 30.
5
Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review.肾细胞癌患者中胰腺神经内分泌肿瘤与胰腺继发性病变的同步或异时表现。系统评价。
Semin Oncol. 2022 Dec;49(6):476-481. doi: 10.1053/j.seminoncol.2023.01.007. Epub 2023 Feb 2.
6
Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.手术与监测治疗分化良好、无功能性胰腺神经内分泌肿瘤:国家癌症数据库 11 年分析。
Oncologist. 2020 Feb;25(2):e276-e283. doi: 10.1634/theoncologist.2019-0466. Epub 2019 Oct 2.
7
Does Prior Cancer Have an Influence on the Survival Outcomes of Patients with Localized Pancreatic Neuroendocrine Tumors?既往癌症是否会影响局限性胰腺神经内分泌肿瘤患者的生存结局?
Chin Med Sci J. 2021 Dec 31;36(4):284-294. doi: 10.24920/003803.
8
Pre- and intraoperative diagnostic requirements, benefits and risks of minimally invasive and robotic surgery for neuroendocrine tumors of the pancreas.胰腺神经内分泌肿瘤的微创和机器人手术的术前和术中诊断要求、获益和风险。
Best Pract Res Clin Endocrinol Metab. 2019 Oct;33(5):101294. doi: 10.1016/j.beem.2019.101294. Epub 2019 Jul 10.
9
Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors.von Hippel-Lindau 病相关胰腺神经内分泌肿瘤的预防医学。
Endocr Relat Cancer. 2018 Sep;25(9):783-793. doi: 10.1530/ERC-18-0100. Epub 2018 May 10.
10
Systemic Therapy for Pancreatic Neuroendocrine Tumors.胰腺神经内分泌肿瘤的全身治疗
Indian J Surg Oncol. 2024 May;15(Suppl 2):305-314. doi: 10.1007/s13193-024-01908-y. Epub 2024 Mar 2.

引用本文的文献

1
The Silent Presentation of a Non-functioning Pancreatic Neuroendocrine Tumor: A Case Report.无功能性胰腺神经内分泌肿瘤的隐匿性表现:一例报告
Cureus. 2025 Aug 2;17(8):e89256. doi: 10.7759/cureus.89256. eCollection 2025 Aug.
2
Surgical Versus Nonsurgical Management of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.胰腺神经内分泌肿瘤的手术治疗与非手术治疗:一项系统评价与Meta分析
Ann Surg Oncol. 2025 Jul 24. doi: 10.1245/s10434-025-17819-3.
3
Development and validation of a pathomics model for accurate grading of pancreatic neuroendocrine tumors.

本文引用的文献

1
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).替莫唑胺或替莫唑胺联合卡培他滨治疗晚期胰腺神经内分泌肿瘤的随机研究(ECOG-ACRIN E2211)。
J Clin Oncol. 2023 Mar 1;41(7):1359-1369. doi: 10.1200/JCO.22.01013. Epub 2022 Oct 19.
2
Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.苏拉非尼在晚期高分化神经内分泌肿瘤中的应用:一项多中心、单臂、开放标签、Ib/II 期试验。
Clin Cancer Res. 2019 Jun 15;25(12):3486-3494. doi: 10.1158/1078-0432.CCR-18-2994. Epub 2019 Mar 4.
3
用于准确分级胰腺神经内分泌肿瘤的病理组学模型的开发与验证
NPJ Precis Oncol. 2025 Jul 10;9(1):235. doi: 10.1038/s41698-025-01032-2.
4
PAC-1 Synergizes with Sunitinib to Enhance Cell Death in Pancreatic Neuroendocrine Tumors.PAC-1与舒尼替尼协同作用可增强胰腺神经内分泌肿瘤中的细胞死亡。
ACS Pharmacol Transl Sci. 2025 Apr 2;8(4):1140-1151. doi: 10.1021/acsptsci.5c00052. eCollection 2025 Apr 11.
5
Diagnostic Value of Cytology in Pancreatic Endoscopic Ultrasound-Guided Fine Needle Aspiration: Accuracy in Common Epithelial Pancreatobiliary Tumors and the Role of Cell Block Analysis.细胞学检查在胰腺内镜超声引导下细针穿刺活检中的诊断价值:常见上皮性胰胆肿瘤的诊断准确性及细胞块分析的作用
Iran J Pathol. 2025;20(1):98-107. doi: 10.30699/ijp.2024.2036290.3329. Epub 2025 Jan 10.
6
Comprehensive analysis of differential mRNA and circRNA profiles in primary and metastatic pancreatic neuroendocrine tumors.原发性和转移性胰腺神经内分泌肿瘤中差异mRNA和circRNA图谱的综合分析
Biochem Biophys Rep. 2025 Feb 8;41:101935. doi: 10.1016/j.bbrep.2025.101935. eCollection 2025 Mar.
7
A Case Report of Bilateral Adrenal Gland Stereotactic Body Radiotherapy to Manage Hypercortisolemia in a Patient With Ectopic Adrenocorticotropic Hormone (ACTH) Production From a Metastatic Pancreatic Neuroendocrine Tumor.一例转移性胰腺神经内分泌肿瘤异位分泌促肾上腺皮质激素(ACTH)致高皮质醇血症患者行双侧肾上腺立体定向体部放疗的病例报告
Cureus. 2024 Apr 8;16(4):e57852. doi: 10.7759/cureus.57852. eCollection 2024 Apr.
8
Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment.泌乳素分泌型垂体腺瘤:发病机制、临床表现和治疗的男性特异性差异。
Front Endocrinol (Lausanne). 2024 Feb 2;15:1338345. doi: 10.3389/fendo.2024.1338345. eCollection 2024.
9
Models in Pancreatic Neuroendocrine Neoplasms: Current Perspectives and Future Directions.胰腺神经内分泌肿瘤的模型:当前观点与未来方向
Cancers (Basel). 2023 Jul 25;15(15):3756. doi: 10.3390/cancers15153756.
10
Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy (PANcreatic Cancer Dietary Assessment-PanDA).不可切除胰腺癌患者胰腺外分泌功能不全患病率、评估及治疗的前瞻性观察研究(胰腺癌饮食评估-PanDA)
Cancers (Basel). 2023 Apr 13;15(8):2277. doi: 10.3390/cancers15082277.
Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.
177Lu-DOTATATE 治疗功能性胰腺神经内分泌肿瘤的症状和影像学反应。
J Clin Endocrinol Metab. 2019 Apr 1;104(4):1336-1344. doi: 10.1210/jc.2018-01991.
4
Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation.胰腺神经内分泌肿瘤的当前管理:从根治性手术到观察
Gastroenterol Res Pract. 2018 Jul 22;2018:9647247. doi: 10.1155/2018/9647247. eCollection 2018.
5
A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.神经内分泌肿瘤的通用分类框架:国际癌症研究机构(IARC)和世界卫生组织(WHO)专家共识建议。
Mod Pathol. 2018 Dec;31(12):1770-1786. doi: 10.1038/s41379-018-0110-y. Epub 2018 Aug 23.
6
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.NCCN 指南解读:神经内分泌和肾上腺肿瘤,第 2.2018 版。
J Natl Compr Canc Netw. 2018 Jun;16(6):693-702. doi: 10.6004/jnccn.2018.0056.
7
External Beam Radiotherapy in the Treatment of Gastroenteropancreatic Neuroendocrine Tumours: A Systematic Review.胃肠胰神经内分泌肿瘤的外照射治疗:系统评价。
Clin Oncol (R Coll Radiol). 2018 Jul;30(7):400-408. doi: 10.1016/j.clon.2018.03.006. Epub 2018 Mar 31.
8
Long-Term Efficacy, Survival, and Safety of [Lu-DOTA,Tyr]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.《[Lu-DOTA,Tyr]octreotate 治疗胃肠胰和支气管神经内分泌肿瘤患者的长期疗效、生存和安全性》。
Clin Cancer Res. 2017 Aug 15;23(16):4617-4624. doi: 10.1158/1078-0432.CCR-16-2743. Epub 2017 Apr 20.
9
Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.长效奥曲肽联合干扰素α-2b与长效奥曲肽联合贝伐单抗治疗晚期类癌肿瘤患者的III期前瞻性随机对照试验:SWOG S0518
J Clin Oncol. 2017 May 20;35(15):1695-1703. doi: 10.1200/JCO.2016.70.4072. Epub 2017 Apr 6.
10
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.镥[177Lu]奥曲肽治疗中肠神经内分泌肿瘤的3期试验
N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.